Skip to content

Clinical trials

Observational Supranuclear Palsy, Progressive trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Supranuclear Palsy, Progressive Phase: Observational Clear all

65 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20062
20072
20081
20113
20122
20132
20142
20151
20166
20175
20181
20195
20204
20216
20225
20236
20243
20253
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed24
Recruiting18
Unknown status12
Active, not recruiting6
Not yet recruiting5

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Massachusetts General Hospital4
University of Pennsylvania4
University of California, San Francisco3
Beijing Tiantan Hospital2
National Institute of Neurological Disorders and Stroke (NINDS)2
Ospedale Generale Di Zona Moriggia-Pelascini2
University Health Network, Toronto2
Amoneta Diagnostics SAS1
Assistance Publique Hopitaux De Marseille1
Bastyr University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Supranuclear Palsy, Progressive65
Parkinson Disease36
Multiple System Atrophy34
Corticobasal Degeneration29
Lewy Body Disease17
Parkinsonian Disorders13
Alzheimer Disease12
Frontotemporal Dementia10
Amyotrophic Lateral Sclerosis9
Neurodegenerative Diseases7

Trials

Showing 26 to 50 of 65. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.